Citations

Clear

2 citation(s) found for "Shah, Neomi".

0589 Concomitant Aroxybutynin and Atomoxetine (AD109) with GLP-1 Agonists: An Analysis of the SynAIRgy and LunAIRo Trials in Obstructive Sleep Apnea
Strollo, Patrick, Pho, Huy, Shah, Neomi, Schwab, R J, Somers, Virend, Gell, L., Farkas, Ron, Cronin, John, Patel, Sanjay, Somers, Virend K. , Taranto‐Montemurro, Luigi

Mayo Clinic

SLEEPJ | May 9, 2026 | Volume: 49 | Issue: Supplement_1 | Pages: A261-A262

10.1093/sleep/zsag091.0588 Get It

Abstract Introduction AD109, an investigational oral anti-apneic neuromuscular modulator, combines in one tablet the novel antimuscarinic, aroxybutynin (2.5 mg), with the selective norepinephrine reuptake inhibitor, atomoxetine (75 mg). AD109 significantly improved the apnea-hypopnea index and oxygenation vs placebo (PBO) in two phase 3 clinical trials in OSA. This exploratory analysis evaluated concomitant administration of AD109 with glucagon-like peptide-1 receptor agonists (GLP-1 RA) on weight change in OSA. Methods SynAIRgy (NCT05813275; N=646) and LunAIRo (NCT05811247; N=660) were randomized, double-blinded, PBO-controlled, parallel-arm phase 3 trials of AD109 vs PBO in adults with mild-to-severe OSA (AHI >5) who failed or refused positive airway pressure therapy. Participants must have had a body mass index (BMI) 18.5–40 kg/m2 for males / 18.5–42 kg/m2 for females. Participants receiving GLP-1 RA for diabetes were permitted. Body weight was assessed throughout the trials. Results One-hundred and six participants were enrolled in the phase 3 trials taking a GLP-1 RA for diabetes (PBO+GLP-1 RA: n=48; AD109+GLP-1 RA: n=58). In participants receiving a GLP-1 RA with baseline BMI < 30, AD109 reduced weight by 2.7% (vs PBO: -1.4%, P=0.08) and 0.5% (vs PBO: 2.3%, P=0.60) at Week 26 and Week 51, respectively. In participants receiving a GLP-1 RA with baseline BMI 30 to 34.9, AD109 reduced weight by 0.9% (vs PBO: 1.2%, P=0.84) and 2.5% (vs PBO: 3.3%, P=0.85) at Week 26 and Week 51, respectively. In participants receiving a GLP-1 RA with baseline BMI ≥35, AD109 reduced weight by 5.5% (vs PBO: 0.9%, P=0.02) and 11.5% (vs PBO: 3.8%, P=0.04) at Week 26 and Week 51, respectively. Participants not receiving GLP-1 RA (n=979) showed smaller weight reductions across BMI classes; in participants with BMI ≥35, AD109 reduced weight by 1.4% (vs PBO: 0.2%, P=0.002) and 2.8% (vs PBO: 1.4%, P=0.19) at Week 26 and Week 51, respectively. Conclusion In this exploratory analysis using pooled data from SynAIRgy and LunAIRo, results indicate that participants with a baseline BMI ≥35 receiving AD109+GLP-1 RA experienced progressively greater weight loss over time relative to GLP-1 RA alone. Future studies are needed to further evaluate concomitant administration of AD109+GLP-1 RA in OSA. Support (if any) These studies were supported by Apnimed, Inc.
International Consensus Statement on Obstructive Sleep Apnea
Chang, Jolie L. , Goldberg, Andrew N. , Alzoubaidi, Mohammed , Ashbrook, Liza , Auckley, Dennis , Ayappa, Indu , Bakhtiar, H., Bartley, Bethany L. , Billings, Martha E. , Boon, Maurits , Bosschieter, Pien F. N. , Braverman, Itzhak , Brodie, Kara D. , Caesar, Ray, Cahali, Michel Burihan, Cai, Yi , Cao, Michelle , Capasso, Robson , Caples, Sean M., Chang, Corissa P. , Chang, Katherine W. , Chaudhary, Nilika, Cheong, Crystal , Chowdhuri, Susmita , Cistulli, Peter A. , Claman, David M., Collen, Jacob , Coughlin, Kevin , Creamer, Jennifer , Davis, Eric M. , Dupuy-McCauley, Kara , Durr, Megan L. , Dutt, Mohan, Ali, Mazen El, Elkassabany, Nabil , Epstein, Lawrence J., Fiala, Justin A. , Freedman, Neil, Gill, Kirat, Gillespie, M. Boyd , Golisch, Lea, Gooneratne, Nalaka S., Gottlieb, Daniel J. , Green, Katherine K., Gurubhagavatula, Indira , Hayward, Nathan, Hoffmann, Oliver M. G., Holfinger, Steven , Hsia, Jennifer, Huoh, Kevin C. , Inala, Sanjana , Jobanputra, Aesha M. , Johnson, Andrew P. , Junna, Mithri R. , Kado, Jenna T. , Kaffenberger, Thomas M. , Khan, Meena , Kirsch, Douglas B. , Kominsky, Alan, Kryger, Meir H. , Kushida, Clete A. , Kuzniar, Thomas J., Lim, Diane C , Liu, Stanley Yung‐Chuan , MacKay, Stuart G. , Maurer, Joachim T. , May, Anna M. , Mitchell, Ron B. , Mullins, Anna , Nada, Eman , Naik, Sreelatha , Nokes, Brandon , Olson, Michael D. , Pang, Edward B. , Pang, Kenny P. , Perck, Eli Van de , Piccirillo, Jay F. , Pien, Grace W. , Plawecki, Andrea , Quigg, Mark , Ravesloot, Madeline J. L. , Redline, Susan , Rotenberg, Brian , Ryden, Armand, Sarmiento, Kathleen , Sbeih, Firas , Schell, Amy E., Schotland, Helena , Schwab, Richard J. , Seo, Jiyeon , Shah, Neomi , Shelgikar, Anita V., Shochat, Isaac , Soose, Ryan J. , Steele, Toby O. , Stephens, Erika M. , Stepnowsky, Carl , Thaler, Erica R. , Thapa, Sritika, Vries, Nico de, Weaver, Edward M. , Weir, Ian, Wolfe, Lisa F. , Woodson, B. Tucker , Won, Christine , Xu, Josie , Yalamanchi, Pratyusha , Yaremchuk, Kathleen , Yeghiazarians, Yerem, Yu, Jason L. , Zeidler, Michelle , Rosen, Ilene M. , Alt, Jeremiah A , Mohammed, Alzoubaidi , Ashbrook, Liza , Auckley, Dennis , Ayappa, Indu , Bartley, Bethany L , Braverman, Itzhak , Cahali, Michel B , Cai, Yi , Cheong, Crystal S J , Chowdhuri, Susmita , Cistulli, Peter A , Creamer, Jennifer , Dupuy-McCauley, Kara L , Durr, Megan L , Elkassabany, Nabil M , Fiala, Justin A , Gottlieb, Daniel J , Gulati, Arushi , Holfinger, Steven J , Huntley, Colin , Huyett, Phillip , Inala, Sanjana , Ishman, Stacey L , Jobanputra, Aesha M , Kado, Jenna T , Kezirian, Eric J , Kirsch, Douglas B , Kushida, Clete A , Lam, Derek J , Lettieri, Christopher J , Lin, Hsin-Ching , Magalang, Ulysses J , Malhotra, Atul , Mansukhani, Meghna P , Maurer, Joachim T , May, Anna M , Mitchell, Ron B , Mullins, Anna E , Nada, Eman M , Naik, Sreelatha , Nokes, Brandon T , Pack, Allan I , Pien, Grace W , Piper, Amanda J , Ravesloot, Madeline J L , Redline, Susan , Rotenberg, Brian W , Sarmiento, Kathleen F , Schmickl, Christopher N , Shelgikar, Anita Valanju , Shochat, Isaac , Soose, Ryan J , Steele, Toby O , Stephens, Erika , Strohl, Kingman P , Suurna, Maria V , Vanderveken, Olivier M , Yu, Jason L , Rosen, Ilene M , Alt, Jeremiah A. , Barrera, Jose Enrique , Cabrera‐Muffly, Cristina , Chahine, Lana M. , Hoff, Paul T. , Ishman, Stacey L. , Jella, Tarun K. , Kapur, Vishesh K. , Kezirian, Eric J. , Krystal, Andrew D. , Lam, Derek J. , Malhotra, Atul , Mansukhani, Meghna P. , Mokhlesi, Babak , Pack, Allan I , Patil, Susheel P. , Sutherland, Kate

Mayo Clinic

International Forum of Allergy & Rhinology | September 7, 2022 | Volume: 13 | Issue: 7 | Pages: 1061-1482

10.1002/alr.23079 | PMID 36068685 Get It

ABSTRACT Background Evaluation and interpretation of the literature on obstructive sleep apnea (OSA) allows for consolidation and determination of the key factors important for clinical management of the adult OSA patient. Toward this goal, an international collaborative of multidisciplinary experts in sleep apnea evaluation and treatment have produced the International Consensus statement on Obstructive Sleep Apnea (ICS:OSA). Methods Using previously defined methodology, focal topics in OSA were assigned as literature review (LR), evidence‐based review (EBR), or evidence‐based review with recommendations (EBR‐R) formats. Each topic incorporated the available and relevant evidence which was summarized and graded on study quality. Each topic and section underwent iterative review and the ICS:OSA was created and reviewed by all authors for consensus. Results The ICS:OSA addresses OSA syndrome definitions, pathophysiology, epidemiology, risk factors for disease, screening methods, diagnostic testing types, multiple treatment modalities, and effects of OSA treatment on multiple OSA‐associated comorbidities. Specific focus on outcomes with positive airway pressure (PAP) and surgical treatments were evaluated. Conclusion This review of the literature consolidates the available knowledge and identifies the limitations of the current evidence on OSA. This effort aims to create a resource for OSA evidence‐based practice and identify future research needs. Knowledge gaps and research opportunities include improving the metrics of OSA disease, determining the optimal OSA screening paradigms, developing strategies for PAP adherence and longitudinal care, enhancing selection of PAP alternatives and surgery, understanding health risk outcomes, and translating evidence into individualized approaches to therapy.